EORTC protocol 08062

Randomization phase II study of amrubicin as single agent or in combination with cisplatin versus etoposide-cisplatin as first-line treatment in patients with extensive stage SCLC (ES).
Trial StatusClosed to patient entry
DatesDate of activation: 06/11/2006
Closed on : 31/07/2009
Data management at EORTCFull
Phase2
Randomized trialYes
TypeAdvanced
Targeted Sample sizeEORTC Groups: 81 - All Groups: 81
Number of steps1
DrugAmrubicin
Cisplatin (CDDP)
Etoposide (VP 16)
Study StaffMary O'Brien (Study Coordinator) - Royal Marsden Hospital, Sutton
Richard Sylvester (Statistician) - EORTC, Brussels
Steven Deleu (Data Manager) - EORTC, Brussels
Benedicte Marchal (Project Manager) - EORTC, Brussels, benedicte.marchal( at )eortc.be, +32 2 7741078
Type of cancerLung
Participating GroupsEORTC Lung Cancer Group(Coordinating Group)
Protocol summaryLink provided by NCI PDQ
Protocol documents in PDF (requires password)08062.pdf
Back to Protocol section